Načítá se...

Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis

Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. Dyslipidemia is a known adverse effect of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody used in RA treatment. We aimed to assess the effect of TCZ on lipid profile and adipokine levels in RA patient...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Mol Sci
Hlavní autoři: Hoffman, Elinoar, Rahat, Michal A., Feld, Joy, Elias, Muna, Rosner, Itzhak, Kaly, Lisa, Lavie, Idit, Gazitt, Tal, Zisman, Devy
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2019
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6770905/
https://ncbi.nlm.nih.gov/pubmed/31540528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20184633
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!